ACS Pharmacology & Translational Science
October 10, 2025
Milo Moskovitz
2 citations
Prior research has determined that music plays a central role in psychedelic assisted therapy (PAT). While there is a general consensus of the importance of music during PAT, there are only three empirical studies published to date that directly investigate which type of music might best support PAT. Importantly, no review to date has critically analyzed these studies and identified the gaps....
Psychedelic Medicine
October 8, 2025
Pim B. van der Meer, Nout Schukking, Miranda G. Dik et al.
Background: Psychedelics such as lysergic acid diethylamide (LSD) and psilocybin have shown a beneficial effect on substance use disorder (SUD) symptoms. In this systematic review, we aimed to assess the efficacy and safety of psychoactive tryptamines in patients with an SUD or non-substance-related disorder (i.e., gambling disorder) in order to provide a comprehensive overview of the available...
Clinical Chemistry
October 1, 2025
Stephanie Marco
Abstract Background Psychedelic and dissociative drugs, including psilocybin, lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA), and ketamine, have garnered significant interest for their therapeutic potential in treating various mental health disorders. However, their psychoactive properties pose substantial risks when used in contexts requiring unimpaired cognitive...
Brazilian Journal of Science
September 29, 2025
Pinelopi Vlotinou, Konstantinos Christodoulou, Anna Tsiakiri et al.
Classical psychedelics encompass psilocybin, lysergic acid diethylamide (LSD), N, N-dimethyltryptamine (DMT), and mescaline and are psychoactive substances that primarily function as agonists at the serotonin 5-hydroxytryptamine receptors (5-HT). In the immediate term, they modify perception, cognition, emotional state, social processing, and introspection, leading to a subjective mystical...
Brain Disorders
September 23, 2025
Matthew Halma, R. Levy, Joseph Varón
2 citations
Clinicians and researchers are showing increased interest in psychedelic-assisted therapy for patients who don't show improvement from using conventional antidepressants. This updated review integrates recent developments, including data on lesser-studied compounds like DMT and 5-MeO-DMT, findings from large clinical trials, and evolving regulatory landscapes. In treatment-resistant depression,...
International Journal of Molecular Sciences
September 14, 2025
Jacopo Sapienza, Marco Spangaro, Stefano Comai et al.
2 citations
Schizophrenia is a highly polygenic disease, and several genetic variants associated with the disease converge on altered synaptic homeostasis. In particular, the gene encoding complement component 4 (C4) showed the strongest association with schizophrenia, and this protein is involved in complement-dependent and microglia-mediated synaptic pruning. As a matter of fact, microglia are overactive...
Carleton undergraduate journal of science.
September 2, 2025
Kaylee Reid, Dhiral Kot, Argel Aguilar-Valles
Major depressive disorder (MDD) is a complex and debilitating condition affecting approximately 280 million people worldwide. Its heterogeneous nature makes it difficult to establish clinical treatment guidelines that address individual differences in treatment response. As a result, many individuals experience treatment-resistant depression (TRD) failing to respond to first-line...
British Journal of Pharmacology
September 2, 2025
Lucas M Wittenkeller, Gary A. Gudelsky, Theresa Winhusen et al.
3 citations
Abstract Psychedelics have garnered great attention in recent years as treatments for major depressive disorder (MDD) and treatment‐resistant depression because of their ability to alter consciousness and afflicted cognitive processes with lasting effects. We aimed to characterise how psychedelics are currently being investigated to treat substance use disorders (SUDs). Additionally, we aimed...
Journal of Eating Disorders
September 2, 2025
Elena Koning, Riccardo Miceli Mcmillan, Aaron Keshen et al.
3 citations
Psychedelic-assisted therapy (PAT) is an emerging intervention in psychiatry, for which there is preliminary evidence for effectiveness in eating disorders (EDs). The subjective psychedelic experience is considered an important driver of positive outcomes following PAT; however, conventional study design approaches often overlook many of the nuances inherent to the experience. Consequently,...
Contemporary Drug Problems
August 28, 2025
Jason K. Day, Michael Th. Grooff
1 citation
Established by the 1971 United Nations (UN) Convention on Psychotropic Substances, the prohibition of the recreational use of psychedelics (lysergic acid diethylamide [LSD], psilocybin, N , N -dimethyltryptamine [ N , N -DMT], and mescaline) has two premises. First, recreational use poses a serious threat to public health because psychedelics are highly liable to addiction and abuse. Second,...